EXPO

An Open Label, Non-comparative Observational Study to Evaluate the Efficacy and Safety of Olmesartan Medoxomil Tablet 20mg in the Treatment of Mild to Moderate Essential Hypertension for 24 Weeks in Chinese Patients & a Sub-group of ABPM Study to Measure the T/P Ratio and Ambulatory Blood Pressure Change

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080221127

Enrollment

300

Registered

2010-06-10

Start date

2010-06-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild to moderate essential hypertension

Interventions

investigational material(s) Generic name etc : Olmesartan Medoxomil INN of investigational material : Therapeutic category code : 214 Antihypertensives Dosage and Administration for Investigational m

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 90<=SeDBP<110mmHg, SeSBP<180mmHg

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
SeDBP, SeSBP, ABPM and Home BP SeDBP and SeSBP changes from baseline at week 4,8,12,16,20,24 after treatment	—

Secondary

Measure	Time frame
SeDBP, SeSBP, ABPM and Home BP Target rate of SeSBP and SeDBP at each visit respectively Response rate of SeSBP and SeDBP	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026